Pegozafermin offers a distinct mechanism of action with potential for enhanced efficacy and tolerability and opportunities for combination development with incretins
The Phase Ib MAD study is a randomized, double-blind, placebo-controlled trial conducted in the United States
Conducted entirely in Europe across forty sites in five countries, this rigorous study met all clinical endpoints
Merck opens first climate-neutral manufacturing facility in Ireland
Wegovy achieved significant weight loss with one in three study participants losing 20% or more body weight
The lab will facilitate the development of herbal and natural-based solutions
IND application for EB-003 expected in early 2026
Bayer Co.Lab AdVenture platform will accelerate biotech innovation through global investment networks
Pete Pharma will leverage FABRX’s extensive foundation of scientific validation to deliver a commercially viable, pharmacy-ready solution in the US
Subscribe To Our Newsletter & Stay Updated
